aripiprazole monohydrate
Long-acting injectable antipsychotic • Brands: ABILIFY MAINTENA
Last reviewed: 2025-12-30
General information
- Class: Long-acting injectable antipsychotic
- Common US brands: ABILIFY MAINTENA
- Long-acting injectable formulation available.
- Therapeutic drug monitoring not routinely recommended; reference range 120–270 ng/mL.
- Last reviewed: 2025-12-30
Dosing & forms
- Forms/strengths: —
- Frequency: —
- Food: —
- Typical range: —
Mechanism (brief)
Long-acting injectable aripiprazole formulation (D2/D3 partial agonist with 5-HT1A partial agonism and 5-HT2A antagonism) intended for maintenance treatment when monthly dosing supports adherence and relapse prevention.
Metabolism & Half‑life
- Metabolism: CYP2D6, CYP3A4
- Half‑life: Steady-state range 718–1116 h
Therapeutic Drug Monitoring (TDM)
Recommended: No
Reference range: 120–270 ng/mL
Long‑acting injectable (LAI)
Monitoring highlights
- —
Sources
- ABILIFY MAINTENA (aripiprazole) extended-release injectable suspension — Prescribing Information — DailyMed (2025)
- Safety of once-monthly aripiprazole initiation in schizophrenia — Current Medical Research and Opinion (2013)
- The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia — American Psychiatric Association (2020)
- Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017 — Pharmacopsychiatry (2018)